Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Raises $2.5M in Rights Offering

NEW YORK (GenomeWeb News) – GeneNews today announced it has completed its rights offering, raising C$2.6 million ($2.5 million) in gross proceeds.

The Toronto-based molecular diagnostics firm issued a total of more than 23 million common shares under the offering at C$.11 per share. The offering, which was announced in April, was fully prescribed.

Proceeds will go toward the commercialization in the US of GeneNews' lead product, ColonSentry, which was recently launched in New York and New Jersey. The blood-based test is for stratifying the risk for colon cancer.

The company said tha tin connection with the rights offering and the terms of all outstanding common share purchase warrants, effective as the end of the business day on June 5, the exercise price of the warrants has been adjusted to C$.24 from C$.25 and the number of common shares issuable upon the exercise of each warrant has been adjusted to 1.05 shares from 1 share.

As of today, there are 19,981,178 warrants outstanding, GeneNews said.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.